Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B-MAD chemotherapy
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
B-MAD chemotherapy is a combination chemotherapy regimen comprising brentuximab vedotin, methotrexate, L-asparaginase, and dexamethasone. This regimen is under investigation for the treatment of newly-diagnosed Extranodal NK/T-cell Lymphoma (ENKTL). Brentuximab vedotin is an antibody-drug conjugate (ADC) designed to selectively deliver a cytotoxic agent to CD30-expressing cancer cells. Methotrexate functions as an antimetabolite, inhibiting dihydrofolate reductase and thereby disrupting DNA synthesis. L-asparaginase is an enzyme that depletes asparagine, an amino acid crucial for the proliferation of certain cancer cells. Dexamethasone, a corticosteroid, exerts anti-inflammatory, immunosuppressive, and direct cytotoxic effects on lymphoid malignancies.
- Other names
- brentuximab vedotin and methotrexate/ L-asparaginase/ dexamethasone
02
Targets
GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)CD30 (CD30 antigen)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on B-MAD chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B-MAD chemotherapy.